Trastuzumab deruxtecan in HER2-positive state-of-the-art breast cancer cells with or without human brain metastases: a stage 3b\/4 trial

.Attributes Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of people along with HER2+ state-of-the-art bosom cancer cells and energetic or stable brain metastases showed steady intracranial activity and wide spread effectiveness of T-DXd.

Articles You Can Be Interested In

• Literature
• Quantum Computing
• Entertainment
• Logistics
• Psychology
• Science
• Gardening
• Leadership
• PR & Branding
• DIY Projects
• Credit
• Tax Planning
• Teamwork
• Pharmaceuticals
• Ethics
• Philanthropy
• Advertising
• Debt Management
• Tech Updates
• Entertainment